Utrecht

• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA) Pending
  2025-520923-25-00 5 Juvenile Idiopathic Arthritis
• Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem … Pending
  2025-521390-14-00 4 Acute Myeloid Leukemia
• Clinical trial to assess the safety and tolerability of TP-122A for the treatment of ventilator-associated pneumonia. Pending
  2025-521533-85-00 7 Ventilator-Associated Pneumonia
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• A phase 1/2 study of subcutaneous blinatumomab administration in children with R/R and MRD+ B-ALL Pending
  2025-521671-31-00 9 Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+)
• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending
  2025-522019-40-00 9 relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+)
• Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. Pending
  2025-522138-29-00 4 Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with n
• Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial (PIPELINE-RSV) Pending
  2025-522194-11-00 5 Respiratory Syncytial Virus (RSV)
• HOVON 178 WM: Treatment of Waldenstrom’s macroglobulinemia with epcoritamab if the disease comes back during or after previous treatment Pending
  2025-522295-91-00 9 relapsed or refractory Waldenstrom’s macroglobulinemia
• Phase 1/2 study to investigate the safety and preliminary efficacy of GSK5460025 alone or in combination with other anti-cancer agents in dM … Pending
  2025-522318-21-00 7 Neoplasms, Colorectal
• Usnoflast Neuromuscular Investigation for Treatment Efficacy in ALS (UNITE-ALS) Pending
  2025-522580-15-00 4 Amyotrophic Lateral Sclerosis (ALS)
• A Phase 1/2 Study of the Safety and Tolerability of ICM VTx-002 in participants with ALS Pending
  2025-522697-37-00 7 Amyotrophic Lateral Sclerosis
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Pending
  2025-522883-34-00 6 Metastatic cervical cancer
• The INFLUENCE Trial: Improve CAR T cell therapy by optimizing fludarabine exposure Pending
  2025-523096-34-00 5 B-cell Acute Lymphoblastic Leukemia
• PREOPANC-6 study: dendritic cell immunotherapy after FOLFIRINOX chemotherapy in patients with resectable pancreatic cancer Pending
  2025-523134-28-00 10 ABC borderline resectable pancreatic cancer
• SHIELD – Swift Hydrocortisone Intervention after trauma exposure Pending
  2025-523350-13-02 4 Posttraumatic Stress Disorder (PTSD)
• An efficacy and safety study of cenegermin ophthalmic solution compared with vehicle in the treatment of PCED Pending
  2025-523443-35-00 5 Persistent Corneal Epithelial Defect (PCED)
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis. Pending
  2025-523939-18-00 9 Amyotrofic Lateral Sclerosis (ALS)
• AchilleS tendinoPathy treated with cortIcosteRoid injEctions. Pending
  2025-524057-13-00 5 Achilles tendinopathy
• Methotrexate in paediatric and adolescent Crohn’s disease: an observational study Pending
  2025-524129-42-00 6 Crohn’s disease
• Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an … Pending
  2025-524229-41-00 5 Triple negative breast cancer
• A medical research to evaluate if MaaT013 is safe and helps children and adolescent with GI-aGvHD after failed two prior therapies. Pending
  2025-524302-15-00 4 Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

Showing 25–48 of 628 trials